{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "EU ORPHAN DRUG" in comments (approximate match)
Status:
Investigational
Source:
NCT03118570: Phase 2 Interventional Completed Osteogenesis Imperfecta, Type I
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04311697: Phase 2/Phase 3 Interventional Completed Critical COVID-19 With Respiratory Failure
(2020)
Source URL:
Class:
PROTEIN
Aviptadil, a vasoactive intestinal polypeptide, is a vasodilator and lowers blood pressure if administered intravenously. In 2007, the orphan designation was granted by the European Commission for aviptadil for the treatment of sarcoidosis, a disease of unknown cause that affects many organs and tissues, most commonly the lungs. Sarcoidosis is characterized by specific microscopic lesions called granulomas. Aviptadil is able to influence the immune system that decreases the inflammatory processes seen in sarcoidosis by acting on the white blood cells (lymphocytes and monocytes) involved in the formation of the granulomas. In combination with phentolamine, the drug is used to treat erectile dysfunction. In addition, aviptadil has been studied in phase II clinical trials for patients with respiratory distress syndrome.
Status:
Investigational
Source:
NCT01152788: Phase 2 Interventional Completed Melanoma
(2010)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03395704: Phase 2 Interventional Completed Hereditary Hemochromatosis
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01176461: Phase 1 Interventional Completed Melanoma (Skin)
(2010)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:efpegerglucagon [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04317040: Phase 3 Interventional Completed Coronavirus Disease 2019 (COVID-19)
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02869243: Phase 1 Interventional Completed Glioblastoma
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:grisnilimab setaritox [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03406611: Phase 1/Phase 2 Interventional Active, not recruiting Homocystinuria
(2019)
Source URL:
Class:
PROTEIN
